Genetron, a Beijing-based cancer genomics firm, plans to raise up to $175.5 million by offering 13 million American depositary shares (ADS) in an initial public offering on the Nasdaq, according to its amended filing.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
